Page last updated: 2024-11-05

2-hydroxypyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hydroxypyridine : Any member of the class of pyridines with at least one hydroxy substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

pyridin-2-ol : A monohydroxypyridine that is pyridine substituted by a hydroxy group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8871
CHEMBL ID662
CHEBI ID16540
MeSH IDM0068634

Synonyms (107)

Synonym
ai3-19236
2(lh)-pyridinone
einecs 205-520-3
pyridone-2 [french]
nsc 172522
nsc176167
.alpha.-pyridone
nsc-176167
66396-89-2
nsc-172522
2(1h)-pyridone
2(1h)-pyridone, dimer
2-oxopyridine
nsc172522
2-pyridinone
2(1h)-pyridinone
CHEBI:16540 ,
alpha-pyridone
1h-pyridin-2-one
AC-907/25014059
pyridin-2-ol
pyridin-2(1h)-one
pyridinone
930-70-1
2-pyridone
2-pyridinol
2-hydroxypyridine ,
C02502
142-08-5
2-hydroxypyridine, 97%
B910DA2F-8676-4873-9F5A-7A9091749198
sr-1c9
CHEMBL662 ,
FT-0654997
H0330
AKOS000119122
A837610
72762-00-6
hydroxypyridine
pyridin-2-one
unii-6770o3a2i5
6770o3a2i5 ,
pyridone-2
pyridinol
27341-45-3
einecs 276-824-1
1h-2-pyridone
STL146648
FT-0612635
AM20061675
S6360
AKOS016352898
levetiracetam impurity c
BBL027571
levetiracetam impurity, pyridin-2-ol- [usp impurity]
hydroxypyridine, 2-
levetiracetam impurity c [ep impurity]
2-hydroxy pyridine
2-hydroxyl pyridine
1-h-pyridin-2-one
2-hyroxypyridine
2-(1h)-pyridone
pyridin2(1h)-one
pyridinyl alcohol
pyrid-2-one
pyridin-2 (1h)-one
2-pyridyl alcohol
hydroxylpyridine
1,2-dihydro-oxopyridine
hydroxy-pyridine
pyrdinone
lh-2-pyridone
2-hydroxy-pyridine
(1h)-pyridone
2-hydroxypryidine
2h-pyridin-2-one
2-pyridol
1-hydroxy-2-pyridine
tox21_303883
NCGC00357141-01
dtxsid2051716 ,
dtxcid2030271
cas-142-08-5
W-108179
mfcd00006268
F1995-0210
2-hydroxypyridine, purum, >=97.0% (hplc)
2-hydroxypyridine, analytical standard
levetiracetam impurity c, european pharmacopoeia (ep) reference standard
pyridin-2-ol; levetiracetam imp. c (ep); 2-hydroxypyridine; levetiracetam impurity c
Z1245646663
2-pyridinol (acd/name 4.0)
alpha -pyridone
Q209474
1,2-dihydropyridin-2-one
1~{h}-pyridin-2-one
HRZ ,
mfcd00462283
A929205
D87632
P20525
t5y ,
SB52273
SB52270
bdbm50538683
PD144419
EN300-21469

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Challenges with this class of therapeutics remain, including frequency of the dosing regimen and the genetic barrier to resistance."( Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV.
Barbe, G; Campeau, LC; Coleman, PJ; Dubost, D; Embrey, MW; Grobler, J; Hartingh, TJ; Hazuda, DJ; Klein, D; McCabe Dunn, J; Miller, MD; Moore, KP; Nguyen, N; Pajkovic, N; Powell, DA; Rada, V; Raheem, IT; Sanders, JM; Schreier, JD; Sisko, J; Steele, TG; Wai, J; Walji, A; Xu, M, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
monohydroxypyridineA hydroxypyridine carrying a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency27.30600.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
protein foldingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
response to bacteriumPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
chaperone-mediated protein foldingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
protein peptidyl-prolyl isomerizationPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
peptidyl-prolyl cis-trans isomerase activityPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
protein bindingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
FK506 bindingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
protein-macromolecule adaptor activityPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
heat shock protein bindingPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cytoplasmPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
nucleoplasmPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
cytosolPeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
membranePeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
extracellular exosomePeptidyl-prolyl cis-trans isomerase FKBP5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID70689Cell growth was measured on day 3, after murine erythroleukemia cells were exposed at a cell concentration of 1*10e5 cells/mL.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID1136156Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as hemoglobin level per 10'7 cells after 3 to 6 days relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pyridine derivatives as potent inducers of erythroid differentiation in Friend leukemia cells.
AID1649766Binding affinity to 15N-labeled FKBP51 (1 to 140 residues) (unknown origin) expressed in Escherichia coli OD2N by two-dimensional 1H/15N HSQC NMR spectroscopy2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Hybrid Screening Approach for Very Small Fragments: X-ray and Computational Screening on FKBP51.
AID30518Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -4 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID70691Concentration producing the maximum percentage of benzidine-positive cells after 6-days of continuous exposure in murine leukemia cells.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID1649764Binding affinity to 15N-labeled FKBP51 (1 to 140 residues) (unknown origin) expressed in Escherichia coli OD2N assessed as induction of chemical shift perturbations at Ile87 residues by two-dimensional 1H/15N HSQC NMR spectroscopy2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Hybrid Screening Approach for Very Small Fragments: X-ray and Computational Screening on FKBP51.
AID30380Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-41985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1136154Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as cell growth after 3 days relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pyridine derivatives as potent inducers of erythroid differentiation in Friend leukemia cells.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1136153Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as concentration required for maximum proportion of benzidine positive cells after 6 days1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pyridine derivatives as potent inducers of erythroid differentiation in Friend leukemia cells.
AID70690Cell growth was measured on day 6 after murine erythroleukemia cells were exposed at a cell concentration of 1*10e5 cells/mL.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID30391Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 3.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID70688Percentage of benzidine-positive murine erythroleukemia cells on day 6.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.
AID74488Inhibitory activity against murine gelatinase B at 5 mM was determined2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Design and synthesis of novel inhibitors of gelatinase B.
AID303044Cytotoxicity against human MIA PaCa2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
AID1136155Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as benzidine positive cells after 6 days relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pyridine derivatives as potent inducers of erythroid differentiation in Friend leukemia cells.
AID1136157Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as cell growth after 6 days relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pyridine derivatives as potent inducers of erythroid differentiation in Friend leukemia cells.
AID303043Cytotoxicity against human MIA PaCa2 cells after 4 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (196)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (12.24)18.7374
1990's8 (4.08)18.2507
2000's45 (22.96)29.6817
2010's84 (42.86)24.3611
2020's35 (17.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.36 (24.57)
Research Supply Index5.29 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index64.73 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (2.53%)6.00%
Case Studies1 (0.51%)4.05%
Observational0 (0.00%)0.25%
Other192 (96.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]